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ABSTRACT 
Background: Noonan syndrome (NS) is an auto-
somal dominant inherited disease, characterized 
by a distinctive facial appearance, congenital 
heart defects, and short stature. Treatment with 
growth hormone (GH) is an option to enhance 
height, but long-term effects are still unclear. 
Patients and Methods: A cohort of 402 patients 
(269 males, 133 females), mean age 9.7 years at 
start with GH, was studied within the KIGS 
International growth database with respect to 
long-term response to GH therapy and final 
height after GH therapy. 
Results: At the start of GH therapy median 
height was -2.61 SDS (Tanner 1966 standards). 
Seventy-three patients who were followed longi-
tudinally for 3 years had an increment in height 
SDS (Ht SDS) over the first 3 successive years of 
0.54, 0.13 and 0.13, respectively. Twenty-four 
patients had reached their final height after 4-12 
years of GH treatment. Their Ht SDS increased 
from a median of -3.28 to a median of -2.41 at 
final height. 
Conclusion: This group of patients with NS 
showed an early response to GH treatment, with 
an attenuation of this effect thereafter. At final 
height the median increment of final height was 
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0.61 SDS according to Tanner standards and 
0.97 SDS according to Noonan standards. No 
serious side effects were reported. 
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INTRODUCTION 
Noonan syndrome (NS) is a relatively common 
multiple congenital anomaly syndrome, first de-
scribed in 1963 by Noonan and Emke1, with an 
incidence of one per 1,000 live births2·3. The 
inheritance of NS is autosomal dominant, with 
variability in expression. Sporadic mutations occur 
in 50% of patients. A gene was mapped on the long 
arm of chromosome 12 in 1994 4. In 2001 the gene 
was identified as the PTPN11 gene, accounting for 
approximately 50% of all cases5. Currently the 
diagnosis of NS remains mostly clinical. The main 
clinical features are characteristic facial features 
(hypertelorism, ptosis, down slanting palpebral 
fissures, low set posterior rotated ears and webbed 
neck), cardiac defects (most frequent pulmonary 
stenosis and hypertrophic cardiomyopathy; others 
are atrial septal defects, ventricular defects and 
coarctation of the aorta), chest deformity and 
growth retardation with short stature6'7. 
Fifty to 70% of patients with NS have short 
stature ,3'8. Patients with NS have a typical growth 
pattern. Birth height and length are in the normal 
range, but patients fall below the 5th percentile at 
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approximately 3 months of age and remain growing 
below this percentile9'10. Onset of puberty is 
delayed, and bone maturation shows an average 
delay of 2 years. Ranke et al. and Witt et α/.9'10 
recorded final heights from patients with NS. They 
reported mean heights of 162.5 and 161.0 cm in 
males and 152.7 and 150.5 cm in females, respec-
tively. The underlying cause of short stature is 
unclear. Low insulin-like growth factor-I (IGF-I) 
levels have been reported11'12, as well as impaired 
spontaneous growth hormone (GH) secretion11"14. 
GH stimulation tests are reported as normal13. 
Studies with GH for patients with NS have been 
conducted in relatively small patient groups and 
found an increase in height velocity in the short 
term, with a waning effect in the longer term15"17. 
Data on final height are scarce. The effect of GH 
treatment on long-term growth and final height in 
larger groups of patients needs to be assessed. 
We performed a retrospective study in 402 
patients with NS treated with GH, to evaluate the 
long-term effect and the gain in final height. 
P A T I E N T S A N D M E T H O D S 
All patients with a clinical diagnosis of NS who 
were enrolled in the KIGS International growth 
database from January 1985 until December 2004 
were evaluated. Excluded were patients with insuf-
ficient reports on auxological details at the start of 
GH treatment. Auxological data (birth weight, birth 
height, height, height velocity, mid-parental height, 
weight, body mass index [BMI], GH dose and GH 
regimen), biochemical data (maximum growth 
hormone peak) and clinical data (age, sex, country 
of origin, · pubertal stage, adverse events) were 
collected. The total cohort consisted of 402 patients 
(242 male, 118 female) from 27 countries. Sixty-
three percent of the patients originated from 
Europe, 17% from North America, 9% from 
Australia and New Zealand, 1% from South 
America and 10% from Asia. 
Out of the total database of 402 patients, two 
sub-cohorts were formed: one cohort with patients 
who had 3 years of prepubertal follow-up, and one 
cohort with patients who reached near adult height 
on GH treatment. Three years was the longest 
representative period of prepubertal follow-up in 
this study group; after 3 years too many patients 
were lost to follow-up, mostly because of entering 
puberty. 
Prepubertal follow-up was defined as yearly 
reports in patients without any signs of puberty. 
Puberty was defined as Tanner breast stage of at 
least 2 for girls18 and testis volume of at least 4 ml 
for boys. If there were no reports on pubertal 
markers, patients were considered to be in puberty 
if they had a chronological age of at least 10 years 
for girls and at least 12 years for boys. 
Near adult height was defined as height velocity 
less than 2 cm per year, based on intervals of at 
least 9 months (with minimum age above 15.0 
years for girls and 17.0 years for boys). Chrono-
logical age at start of GH treatment was below 14.0 
years for females and 16.0 years for males. At least 
1 year of prepubertal GH treatment was required, 
and at least 4 years of GH treatment in total. 
Reference growth curves were used from Tanner 
and Whitehouse18 for children with normal growth 
and from Ranke et al.9 for children with NS. 
Recombinant GH was given as daily subcutane-
ous injections, with a median dose of 0.24 mg/ 
kg/week (range 0.17-0.77 mg/kg/week). Any 
adverse event occurring during GH treatment was 
reported by body system (musculoskeletal, ner-
vous, cardiovascular, respiratory, gastro-intestinal, 
metabolic and endocrine, hematological, urinary, 
reproductive and psychiatric). 
Statistical analysis was by SAS and Windows 
XP Excel. 
The study was reviewed and approved by an 
institutional ethics committee of the participating 
hospitals. Written informed consent was obtained 
from all patients and parents of patients involved in 
this study. 
R E S U L T S 
Baseline characteristics are shown in Table 1. 
Data from both sexes were pooled, since there were 
no significant differences between them. 
Median birth weight and median birth length 
were -0.38 SDS and -0.69 SDS, respectively, 
according to Tanner standards. Mid-parental height 
was -0.41 SDS according to Tanner standards. The 
median maximal GH peak was 10 μg/I (measured 
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TABLE 1 
Baseline characteristics of the total cohort of patients with Noonan syndrome 
η Median 10Λ percentile 90th percentile 
(total = 402) 
Gestational age (weeks) 375 40.00 36.00 41.00 
Birth weight SDS 366 -0.38 -2.13 1.01 
Birth length SDS 243 -0.69 -2.55 1.40 
Midparental height SDS 368 -0.41 -2.09 1.28 
Max. growth hormone peak ^ g / l ) 298 10.00 4.60 28.00 
TABLE 2 
Data at the start of growth hormone (GH) therapy of the total cohort of patients with Noonan syndrome 
η Median 10th percentile 90th percentile 
(tota 1= 402) 
Chronological age (yr) 402 9.73 4.59 14.38 
Bone age (yr) 109 7.30 2.25 11.90 
Height SDS 402 -2.95 -4.29 -1.94 
Height velocity (cm/yr) 182 4.39 2.89 6.45 
Height - MPH SDS 368 -2.54 -4.53 -0.77 
Weight SDS 402 -2.61 -4.13 -1.17 
BMI SDS 402 -0.50 -1.87 1.00 
Dose of GH (mg/kg/week) 402 0.24 0.16 0.36 
Frequency of injections 402 7.00 6.00 7.00 
MPH = mid-parental height; BMI = body mass index. 
in 298 patients) and only a minority of patients had 
a stimulated GH value in the deficient range. 
Data at start of GH treatment for all 402 patients 
are shown in Table 2. 
Three year longitudinal prepubertal follow-up 
was available in 73 patients. Baseline characteris-
tics and background data at the start of GH 
treatment and in the first and second year of follow-
up were not statistically different from the total 
cohort. Median age at start was 7.73 years, median 
height was -2.86 SDS according to Tanner stan-
dards, and -1.04 SDS according to Noonan 
standards, median weight was -2.20 SDS, with a 
median BMI of -0.62 SDS. Height velocity, height 
SDS and bone age advancement during three years 
of GH therapy are shown in Figures 1-3. Height 
velocity almost doubled in the first year, declined 
after 2 and 3 years, but remained approximately 1 
cm/year higher after 3 years than at the start of 
treatment. 
Height SDS increased by 0.76 SDS, with most 
gain during the first year and a smaller but constant 
gain during the second and third years of GH 
therapy. The increase according to Noonan stan-
VOLUME 21, NO. 3,2008 
Brought to you by | Radboud University Nijmegen (Radboud University Nijmegen)
Authenticated | 172.16.1.226
Download Date | 7/13/12 12:22 PM













A I 2 6 
\ _ 5 . 9 3 / • ·5.β7 / 
¥ 4 82 
Fig. 1: 
start year 1 year 2 year 3 
Height velocity during 3 years o f growth hormone 
treatment in patients with Noonan syndrome. 
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Fig. 2: Height standard deviation score (Ht SDS) during 3 
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Fig. 3: Bone age advancement during 3 years o f growth 
hormone treatment in patients with Noonan 
syndrome. 
dards during the first, second and third year was 
0.53, 0.22 and 0.15, respectively. The total increase 
in height SDS according to Noonan standards after 
3 years was 0.81 SDS. Bone age increased from a 
median of 6.0 years at the start to a median of 9.3 
years after 3 years of GH treatment. 
Near adult height after at least four years of GH 
treatment was reached in 24 patients. Baseline 
characteristics and background data were not 
significantly different from the total cohort. Median 
age at start of GH treatment was 10.17 years, with a 
median height SDS of -3.24. Median duration of 
GH treatment was 7.59 years. The gain in height 
SDS per patient is shown in Figure 4. Median gain 
in height SDS according to Tanner standards was 
patient number 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
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Fig. 4: Height standard deviation score (Ht SDS) at start o f growth hormone treatment (black bars) and at near adult height (white 
bars) in patients with Noonan syndrome. 
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0.61. Thirteen of the 24 patients (54%) had a final 
height below -2 SDS (Tanner standards), compared 
to 23 of the 24 patients (96%) at the start of GH 
treatment. Median gain in height SDS according to 
Noonan standards was 0.97 SDS. Bone age 
advanced from a median of 7.0 years (delay 3.17 
years) to a median of 15.7 years (delay 2.74 years). 
No serious adverse events in relation to GH 
treatment were observed. 
One hundred and twenty eight patients dis-
continued GH treatment before reaching final 
height (31.8%). The main reasons mentioned are 
shown in Table 3. The group who discontinued 
treatment had a smaller response in height SDS 
after 1 year than the group that was treated for 3 
years (mean 0.42 vs 0.53, median 0.42 versus 0.42), 
but this was not statistically significant. 
DISCUSSION 
This study provides an analysis of long-term GH 
treatment in a large group of patients with NS. 
There was a median gain in final height of 0.61 
SDS according to Tanner standards and 0.97 SDS 
according to Noonan standards. Thus there was a 
significant but relatively small increase in final 
height. More than 50% of the patients reached a 
final height above -2 SDS (Tanner), whereas more 
than 95% of patients had a height below -2 SDS at 
the start of treatment. In our opinion, it is an 
important result in this lower height range for 
patients to achieve a final height above -2 SDS, 
within the socially accepted 'normal' range. 
NS remains a clinical diagnosis, and thus 
making the correct diagnosis depends on the 
individual observer. The development of scoring 
systems8'19,20 partly solves this problem, but estab-
lishing the correct diagnosis remains a limitation in 
studies on patients with NS. However, we assume 
that the diagnosis was made correctly in our study, 
because it was made by experts on the basis of 
clinical characteristics. In addition, Turner's syn-
drome was excluded by chromosomal analysis. 
The auxological data of our study group at birth 
were slightly below normal, which reflects the data 
reported in the literature, but the median height at 
start of treatment is in the lower height range for 
patients with NS. Presumably our study group 
VOLUME 21, NO. 3,2008 
TABLE 3 
Discontinued patients: reasons for discontinuation 
Reason for discontinuation η (total = 128) 
Poor response 31 
Parents' decision 10 
Lost to follow up 10 
Non-compliance 12 
Normal height reached 6 
Other 59 
represents a pre-selection of short patients with NS, 
because these patients are more likely to be referred 
for GH treatment. The parents of the patients are 
also relatively short. This may partly reflect the fact 
that there would be some parents with NS, and the 
selection bias for GH treatment, which may reflect 
the inheritance of short stature due to other causes 
from the patients' parents. 
There were more male patients than female 
patients in the study group. The male preponde-
rance might reflect male preferential inheritance21, 
or less acceptance of short height in boys22. The 
drop-out proportion in this study was 31.8%. We 
observed a smaller response in the first year in the 
drop-out group compared to the long-term treat-
ment group. Therefore, the long-term effect of GH 
we have reported may be a slight overestimation of 
the benefit of treatment for the total group. 
Previous GH studies conducted in patients with 
NS are scarce and performed with relatively low 
numbers of patients. The gain in height SDS after 
treatment with GH is significant in the short term, 
but the observed effects are variable in the long 
term. De Schepper et α/.15 treated 23 prepubertal 
patients with recombinant human GH at a dose of 
0.35 mg/kg/week for 1 year. They found a mean 
increase in growth velocity of 4.0 cm/yr, and an 
increment in height SDS of 0.53, without accelera-
tion of bone maturation. In patients treated with GH 
for 3 years, Noordam et al.17 found acceleration in 
bone maturation: 1.2 year/year versus 0.5 year per 
year in a control group. Gain in final height seemed 
to be compromised by this accelerating effect, with 
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a mean gain in height SDS corrected for bone age 
of only 0.3. The only larger study, performed by 
Kirk et al.16 in 66 patients, found a mean increment 
in height SDS of 0.6 in 3 years. In the ten patients 
in the study by Kirk et al. who reached near final 
height, the authors did not find a substantial 
improvement in final height, but duration of GH 
treatment was shorter compared to our study group 
(5.15 years versus 7.59 years). In the current study 
GH dosage was relatively low so the effect on final 
height would probably be better with a higher 
dosage, as used in the follow-up study by Noordam 
et al.xl. 
The benefits of GH treatment need to be 
measured against the burden of GH treatment. In 
our study no serious adverse events in relation to 
GH were reported. The reasons for discontinuation 
partly reflect the practical burden of GH treatment 
(non-compliance, problems with injections), as well 
as the high costs of GH treatment. The high costs of 
GH therapy have to be carefully counterbalanced 
against the gain in height. Lee et al. estimated the 
potential cost of GH therapy to be around 52,000 
dollars per 2.54 cm of gain in height . Although 
the estimate in that article was based on patients 
with idiopathic short stature, it gives an indication. 
The patients in the lower height range may benefit 
most from GH treatment, because with a relatively 
small gain in final height they still reach a socially 
more acceptable final height. The balance between 
the - significant but small - gain in height and the 
burden and costs of treatment needs to be con-
sidered in every patient. 
CONCLUSIONS 
In this study we found an early response to GH 
treatment with a waning effect thereafter. However, 
after 3 years of GH treatment there is still a gain in 
height SDS and at near adult height the gain was 
0.61 SDS and 0.97 SDS, according to Tanner 
standards and Noonan standards, respectively. 
More than 50% of patients reached a final height 
above -2 SDS according to Tanner standards. 
GH treatment is effective in NS without adverse 
side effects but the benefit and burden of treatment 
need to be considered when counselling patients 
about potential GH therapy in this condition. 
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